Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis
Endophthalmitis
About this trial
This is an interventional treatment trial for Endophthalmitis
Eligibility Criteria
Inclusion Criteria:
- Patients with acute endophthalmitis with a history of ocular surgical procedures and a follow-up time of less than 6 weeks will be included.
Exclusion Criteria:
- Patients with endophthalmitis lasting more than 6 weeks and no history of eye surgery will be excluded.
Sites / Locations
- Dept of Ophthalmology - UNIFESP/Hospital São Paulo
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Group 1: Antibiotic injection
Group 2: Pars Plana Vitrectomy
A total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected with a 30-gauge needle into the vitreous cavity of the affected eyes in the randomized group, as soon as the diagnosis is confirmed.
Randomized patients will undergo PPV. Briefly, a blepharostat will be placed followed by instillation of a drop of 5% iodine-povidone over the eye. Under a surgical microscope, three 23-gauge or 25-gauge sclerotomies will be performed. Vitreous core vitrectomy will be performed, and a fluid-gas exchange with balanced saline solution (BSS) or 5,000 grams of silicone oil as a vitreous substitute. At the end of surgery, all sclerotomies will be sutured with Vicryl 7.0 and a total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected into the vitreous cavity. As soon as the diagnosis is confirmed.